

Stem Cells in Regenerative Medicine: Potential Clinical Applications

Sevil M^{1,2}, Petek M², Selin R¹, Blatche P¹, Yersal A³

¹LAAS-CNRS, Toulouse, France

²Université Paul Sabatier, Toulouse,

France ³PharmadeV, Toulouse, France



Abstract (Limit 600words)

Stem cells are a type of undifferentiated cell that has the ability to multiply indefinitely (self-renewal), usually from a single cell (clonal), and develop into various cell and tissue types (potent). There are a variety of stem cell sources available, each with varied levels of potency. Pluripotent cells are embryonic stem cells developed from the embryo's inner cell mass, and induced pluripotent cells are derived from somatic cells that have been reprogrammed. All three germ layers have pluripotent cells that can develop into tissue (endoderm, mesoderm, and ectoderm). Multipotent stem cells can differentiate into tissue such as mesenchymal stem cells, which generate adipose tissue, bone, and cartilage, from a single germ layer. Because they can create terminally differentiated cells of a single tissue, tissue-resident stem cells are oligopotent. In cellular treatment, stem cells can be employed to repair damaged cells or rebuild tissues. Furthermore, stem cells have improved our understanding of both development and disease causation. Cell lines that are particular to a disease can be produced and employed in medication research. Despite considerable advancements in stem cell biology, ethical concerns about embryonic stem cells, tumour development, and rejection limit their application. Many of these constraints, however, are being overcome, which could lead to significant advancements in disease management. This article provides an overview of stem cells, including their definition, origin, and categorization, as well as their applications in regenerative medicine.

Stem cells are a prospective source of regenerative medicine for curing a variety of diseases that are now treated with palliative or symptomatic relief or by avoiding the start and progression of the disease. Degenerative alterations in stem cells, stem cell habitats, and communication pathways caused by ageing lead to a gradual loss in tissue regeneration and functional potential. Clinical research and experiments on model organisms have identified checkpoints that ageing will unavoidably impose on stem cells destined for transplantation, raising concerns about the donor's age. The following discussion will go through the basic molecular processes involved in stem cell ageing, as well as the present state of tissue engineering and stem cell transplantation in regenerative medicine. We also look at the effects of stem cell ageing on clinical applications and the creation of new ways to avoid the pitfalls and increase tissue regeneration. With recent advancements, a regenerative medicine approach requires a dual examination of germ and somatic stem cell niches. It is necessary to examine the microenvironments of such niches in relation to numerous components in order to gain a better understanding of the niche idea. Sertoli cells, Leydig cells, vascular endothelial cells, epididymal fat cells, and peritubular myoid cells make up the cellular environment of spermatogonial stem cells, whereas hematopoietic stem cells have mesenchymal stem cells, osteoblasts, osteoclasts, megacaryocytes, macrophages, vascular endothelial cells, pericytes, and adipocytes in their Not only the influence of those cells, but also hormones, growth factors, chemokines, cytokines, extracellular matrix components, biomechanical forces (such as shear stress, tension, or compression), and physical environmental conditions such as temperature, Because the microenvironment is recognised to have a key role in stem cell homeostasis and disease situations, it is critical to comprehend the microenvironment's intricacies and be able to compare the niche ideas of different types of stem cells for regenerative therapies. Indeed, the goal of this chapter is to highlight the importance of niche engineering in future regenerative medicine research. Scaffolds that are decellularized, synthetic, or non-synthetic may be used to imitate the stem cell niche. To create a good niche model, however, the shared or dissimilar properties of germ and somatic stem cell microenvironments are required.

Biography (Limit 200words)

Sevil is a Senior Nurse Therapist and a researcher who has developed a technique called Rebinding of the Body which helps people recover from hormones; growth factors learn self-help techniques and lead more productive lives. Her intersubjective ethnographic study has been published in a text called, "Stem Cells in Regenerative Medicine, Connection and disconnections in Regenerative Medicine treatment". She has published several articles in child and family psychiatry including an extensive literature review called "The Health Impact". Presently, she has a small private practice and she works as a consultant for Cogenz and Thought Leadership and Innovation Foundation. She graduated from the University of Western Ontario with Doctor of Philosophy in Nursing in 2009. Her dissertation was "Seeking and Obtaining Help for Regenerative Medicine. To create a good niche model. To create a good niche model, however, the shared or dissimilar properties of germ and somatic stem cell microenvironments are required. Stem cells can be employed to repair damaged cells or rebuild tissues and completed research in LAAS-CNRS, Toulouse, France.

Importance of Research (Limit 200words)

In theory, the simplest method to regenerative medicine and the one most likely to result in robust regenerative tissue growth would appear to be the use of stem cells themselves, but those that are used in ways that are not predicted to result in robust regenerative tissue growth are rare. They had been mistreated to the point where they were no longer useful tumorigenic. Of course, there was no such methodology at the time. Due to the substantial propensity of hESC to generate teratoma, the idea of employing stem cells directly for transplantation appears to be out of favour with regulators. Selective purging is a similar philosophical approach. Eliminating cancerous cells from the bone marrow, resulting in improved safety Hematopoietic stem cell transplantation has not always been successful. However, given the abundance of cancerous cells, this may be a considerably more difficult task. There is still optimism that mixed populations of tumorigenic and nontumorigenic stem cells can be separated or that the tumorigenic fraction can be targeted selectively. Furthermore, when the molecular processes by which stem and tumour cells are programmed are mapped out, differences will emerge, and those distinct characteristics may pave the way for ways to reduce tumorigenicity while maintaining pluripotency.

About institute (Limit 200words)

LAAS, located in Toulouse, France, is a research unit of the CNRS, the French National Center for Scientific Research, within the Department of Information and Engineering Sciences and Technologies. LAAS is associated to the University of Toulouse (Universities Paul Sabatier, Institut National Polytechnique de Toulouse, Institut National des Sciences Appliquées de Toulouse). The research topics of LAAS, fundamental or applied, are focused on the study of complex systems at different scales with a multidisciplinary and systemic vision and an integrative approach. With 750 researchers, university faculty, technicians, post-docs and PhD students, LAAS is one of the key players in Systems research in the Midi-Pyrénées region, in France and in Europe.



References (Limit 15 – 20)

1. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007;131:861-72. [10.1016/j.cell.2007.11.019](https://doi.org/10.1016/j.cell.2007.11.019)
2. Bianco P, Riminucci M, Kuznetsov S, Robey PG. Multipotential cells in the bone marrow stroma: regulation in the context of organ physiology. *Crit Rev Eukaryot Gene Expr*. 1999;9:159-173.
3. Friedenstein AJ. Osteogenic stem cells in the bone marrow. *Bone Min Res*. 1990;7:243-272.
4. Owen M. Marrow stromal stem cells. *J Cell Sci*. 1988;10:63-76.
5. Pountos I, Giannoudis PV. Biology of mesenchymal stem cells. *Injury*. 2005;36:S8-S12.
6. Pittenger MF, Mackay AM, Beck SC. Multilineage potential of adult human mesenchymal stem cells. *Science*. 1999;284:143-147
7. Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. *Hepatology* 2007;46:219-28. [10.1002/hep.21704](https://doi.org/10.1002/hep.21704)
8. Lotfinegad P, Shamsasenian K, Movassaghpour A, et al. Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy. *Adv Pharm Bull* 2014;4:5-13.
9. Kalra K, Tomar P. Stem Cell: Basics, Classification and Applications. *American Journal of Phytomedicine and Clinical Therapeutics* 2014;27:919-30.
10. Trigg ME. Hematopoietic stem cells. *Pediatrics* 2004;113:1051-7.
11. Fathi E, Farahzadi R. Zinc Sulphate Mediates the Stimulation of Cell Proliferation of Rat Adipose Tissue-Derived Mesenchymal Stem Cells Under High Intensity of EMF Exposure. *Biol Trace Elem Res* 2018;184:529-35. [10.1007/s12011-017-1199-4](https://doi.org/10.1007/s12011-017-1199-4)
12. Lai CY, Wu PJ, Roffler SR, et al. Clearance kinetics of biomaterials affects stem cell retention and therapeutic efficacy. *Biomacromolecules* 2014;15:564-73. [10.1021/bm401583b](https://doi.org/10.1021/bm401583b)
13. Eckert MA, Vu O, Xie K, et al. Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. *J Cereb Blood Flow Metab* 2013;33:1322-34. [10.1038/jcbfm.2013.91](https://doi.org/10.1038/jcbfm.2013.91)
14. Srirood N, Bootcha R, Petchdee S. Foal Deciduous Teeth Stem Cells Enhance Wound Healing in Rabbit Wound Model. *The Thai Journal of Veterinary Medicine* 2016;46:155-61.
15. Lin Y-C, Grahovac T, Oh SJ, et al. Evaluation of a multi-layer adipose-derived stem cell sheet in a full-thickness wound healing model. *Acta Biomaterialia* 2013;9:5243-50. [10.1016/j.actbio.2012.09.028](https://doi.org/10.1016/j.actbio.2012.09.028)

NOTE: This is a sample abstracts. Conference/Journal name will be changed while publishing respective abstract in supporting journal website.